Taking the question as asked, rather than the general version of it. Extending the interval and reducing the dose are pharmacologically different. Reducing the dose lowers the whole exposure curve evenly; extending the interval keeps the peak and drops the trough. Since the appetite effect tracks the trough, interval extension tends to give you good days and bad days rather than a uniformly smaller effect, which most people find harder to live with.
I am eight weeks into deliberately reducing rather than stopping, and the appetite change came back faster than the weight did.
What I am after is whether extending the interval works as well as reducing the dose, since they are not the same intervention pharmacologically.
I would rather have one careful answer than five confident ones.
LabKate said:Extending the interval and reducing the dose are pharmacologically different.
Agreed, and reference ranges are laboratory-specific. Comparing your number to somebody else's range, or to a screenshot from another country, is how people convince themselves something is wrong.
That is the short version; the long version is somebody else's post.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference Standardsquinn_sf said:I am eight weeks into deliberately reducing rather than stopping, and the appetite change came back faster than the weight did.
This matches mine closely enough to be worth saying so. STEP 4 is the study that answers this and it is blunt. Participants who continued kept losing; participants switched to placebo regained about two thirds of what they had lost within a year, and the metabolic improvements faded with the weight. That is the same pattern as every other chronic-disease medication ever withdrawn, and it is an argument about the condition rather than about the drug.
Adding the clinical framing, because it changes how the question reads.
Epigenetic implications of GLP-1 therapy and maintenance dosing: emerging evidence suggests that sustained weight loss and metabolic improvement may produce epigenetic changes (DNA methylation, histone modification) that persist beyond drug discontinuation[1].
This is speculative but fascinating: could long-term GLP-1 agonist treatment "reprogram" metabolic gene expression? If so, it would explain why some patients maintain weight loss better than others after discontinuation.
More research needed, but the concept of pharmacologically-induced epigenetic remodeling is intellectually exciting.
[1] Ling C, et al. Diabetologia. 2023;66(6):1078-1093.